Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Drug Profile

Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Alternative Names: Hepatitis B vaccine - ISA Pharmaceuticals; HPV SLP®-AMPLIVANT™ vaccine; HPV16-peptides-AMPLIVANT-vaccine; ISA 203; ISA-204; Peptide vaccines - ISA Pharmaceuticals; PRAME vaccine; SLP-AMPLIVANT-conjugate-head-and-neck-cancer-vaccine; SLP® vaccines; SLP®-AMPLIVANT™ conjugate vaccines; SLP®-AMPLIVANT™ melanoma vaccine

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Hepatitis B vaccines; Peptide vaccines; Tuberculosis vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Hepatitis B; Viral infections
  • No development reported Tuberculosis

Most Recent Events

  • 08 Sep 2016 Preclinical trials in Hepatitis B in Netherlands (unspecified route) (ISA Pharmaceuticals pipeline, September 2016)
  • 24 Mar 2015 ISA Pharmaceuticals receives a European patent (EP 2 155 240) for the intradermal administration of synthetic long peptides based on HPV oncogenes
  • 15 May 2014 No development reported for Tuberculosis in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top